Romiplostim (Nplate®)

Assessment Status Rapid Review Complete
Drug Romiplostim
Brand Nplate®
Indication Is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Assessment Process
Rapid review commissioned 16/06/2019
Rapid review completed 18/07/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of romiplostim compared with the current standard of care.

The Applicant is seeking reimbursement under the High Tech Drug Arrangements.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.